Aging & Elder Health Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging & Elder Health Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CytRx Corporation
Biopharmaceutical company tackles ALS using two new approaches
January 9th, 2005
CytRx Corporation (CYTR) is researching potential therapies for ALS (Amyotrophic Lateral Sclerosis or Lou Gehrig disease)using both orally administered small molecules and RNA interference (RNAi), one of the most talked-about recent scientific breakthroughs. ALS is a disorder affecting the function of nerves and muscles. Over 5,600 people in the U.S. are diagnosed with ALS each year (15 new cases a day). It is estimated that as many as 30,000 Americans have the disease at any given time, with at least 120,000 people afflicted worldwide. The life expectancy of an ALS patient averages between 2 and 5 years from the time of diagnosis, and only half of all affected live...
Source: Aging & Elder Health Week (2005-01-09)
|
